Lastly, we demonstrate that administering FMF-04-159-2 in vivo reduces α-Syn dosage and, consequently, decreases pathogenic forms of α-Syn in a humanized mouse line expressing PD-linked A53T SNCA. Collectively, these results show that CDK14 is a pharmacologically tractable target for synucleinopathy. This evidence concerns the gene CDK14 and synucleinopathy.